Author: Dr Sarah Eminli-Meissner

    Head of Business – Stem Cells
    and Global Director, Commercial R&D

    5 factors to consider when planning a stem cell reprogramming project

    When you are planning a project involving stem cell reprogramming, there are several factors to consider when choosing a reprogramming technology and a service provider. This post will highlight 5 questions you may want to answer before choosing a service provider or reprogramming technology.

    Continue reading 

    Tissue Sourcing for the Development of iPSC-derived Disease Models

    Human induced pluripotent stem cells (iPSCs)-based models are an ideal resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by drug treatment[3]. Such iPSC-based models enable studies to be performed under defined experimental conditions and in a reproducible manner.

    Continue reading